Reference priceUSD $630.00Original source price: INR 52,500.00. Converted estimates are available by currency selection.
| Brand | Rozlytrek Kaps |
|---|---|
| Manufacturer | Roche Pharma AG |
| Prescription required | Yes |
Rozlytrek Kaps 100mg x 30Stk(Entrectinib)
Entrectinib
Description
Rozlytrek Kaps 100mg x 30Stk(Entrectinib) is a medicine catalog record in the MediPriceHub database. Active ingredient: Entrectinib. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: Roche Pharma AG. Therapeutic category: Medicine Library > Oncology Medicines > Lung Cancer Medicines. Pack information: 100 / 30. Origin country or market: Switzerland. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.Benefits
ROZLYTREK is a kinase inhibitor indicated for the treatment of: This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. Adult patients with ROS1- positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. Adult and pediatric patients older than 1 month of age with solid tumors that: have a neurotrophic tyrosine receptor kinase ( NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy. have a neurotrophic tyrosine receptor kinase ( NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy.How to Use
Use Entrectinib under the supervision of a qualified healthcare professional. Use it only according to the approved label and the instructions of a qualified healthcare professional. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.Specification
Active ingredient: Entrectinib. Pack size: 100 / 30. Pack unit: bottle. Manufacturer: Roche Pharma AG. Origin country: Switzerland. Source category: Medicine Library > Oncology Medicines > Lung Cancer Medicines. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.Side Effects
Cancer medicines may cause fatigue, nausea, vomiting, diarrhea or constipation, appetite changes, mouth sores, rash, changes in blood counts, infection risk, liver or kidney test changes, bleeding risk, neuropathy, infusion reactions, or organ-specific toxicity depending on the medicine. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, confusion, serious bleeding, signs of infection, or rapidly worsening symptoms. The approved local prescribing information is the controlling source for the complete adverse-reaction profile.This information is for reference only. Consult a qualified healthcare professional before using any medicine.